Anti-beta 2 glycoprotein I antibodies in a general obstetric population: preliminary results on the prevalence and correlation with pregnancy outcome. Anti-β2 glycoprotein I antibodies are associated with some obstetrical complications, mainly preeclampsia-eclampsia

Faden, D; Tincani, Anǵela; Tanzi, P; Spatola, L; Lojacono, Andrea; Tarantini, M; Balestrieri, G.

doi:10.1016/s0301-2115(97)02736-x

Cited by 86 publications

(63 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Importantly, even studies reporting an association between significantly elevated aPL and preeclampsia demonstrate low positive predictive values for these antibodies in predicting preeclampsia. For example, in the study by Faden et al [36], women with elevated levels of anti-2 -GPI only had a 10% rate of developing preeclampsia, which is only mildly increased above expected rates for a general obstetric population. Such low predictive values are of limited if any clinical utility in managing the patient with asymptomatic aPL.…”

Section: Discussionmentioning

confidence: 88%

See 1 more Smart Citation

Do antiphospholipid antibodies cause preeclampsia and HELLP syndrome?

Clark

Silver

Branch³

2007

Curr Rheumatol Rep

View full text Add to dashboard Cite

Antiphospholipid syndrome (APS) is associated with adverse pregnancy outcomes including preeclampsia, recurrent early pregnancy loss, fetal death, and intrauterine growth restriction. Approximately one third of women with APS will develop preeclampsia during pregnancy. The association between antiphospholipid antibodies (aPL) in the absence of the clinical syndrome and preeclampsia is less clear, and a causal relationship has not yet been proven. Testing for aPL should be considered in women with early-onset (< 34 weeks) severe preeclampsia, eclampsia, or HELLP (hemolysis, elevated liver enzymes, and low platelets) syndrome, especially when additional clinical features of APS are present. Prospective testing for aPL in women at risk for preeclampsia is not recommended. Current evidence does not justify inclusion of preeclampsia as a major criterion for APS, but preeclampsia could reasonably be included as a secondary or minor criterion in diagnosis when a patient has other clinical features of APS.

show abstract

Section: Discussionmentioning

confidence: 88%

“…Of women with positive tests for aPL, 11% to 50% developed preeclampsia, in comparison to 2% to 4% of those testing negative. In a prospective study of 510 healthy pregnant women, those with elevated anti-2 -GPI antibodies had a higher incidence of preeclampsia (10%) than those testing negative (0.8%) [36].…”

Section: Prospective Cohort Studiesmentioning

confidence: 97%

Do antiphospholipid antibodies cause preeclampsia and HELLP syndrome?

Clark

Silver

Branch³

2007

Curr Rheumatol Rep

View full text Add to dashboard Cite

show abstract

“…Moreover, antiphosphatidylserine and antiphosphatidylcholine antibodies tested in women with recurrent pregnancy loss and preeclampsia have not been established independent of aCL and LA [17]. On the other hand, antibodies to the cofactor ß 2 -glycoprotein I (ß 2 -GPI) have been associated with obstetrical complications, mainly preeclampsia-eclampsia, even if other conventional APL are not present [18,19].…”

Section: Discussionmentioning

confidence: 99%

Anticardiolipin Antibodies and the Severity of Preeclampsia-Eclampsia

Martı́nez-Abundis

González-Ortı́z

Cortés-Llamas

et al. 1999

Gynecol Obstet Invest

View full text Add to dashboard Cite

Objective: To identify and compare anticardiolipin antibodies (aCL) in patients with eclampsia, different grades of preeclampsia and women with normotensive pregnancy. Methods: A cross-sectional study was conducted in 13 patients with eclampsia, 39 with preeclampsia (13 severe, 26 mild), and 52 normotensive pregnant women. All of them were studied in the 3rd trimester of pregnancy. The aCL were determined by an ELISA method. Results: There were no significant differences in IgG aCL (F = 0.33, p = 0.80) and IgM aCL (F = 1.64, p = 0.18) between patients with eclampsia (6.9 ± 3.9 U/GPL and 4.0 ± 2.0 U/MPL), severe preeclampsia (5.7 ± 3.5 U/GPL and 2.9 ± 1.3 U/MPL), mild preeclampsia (6.8 ± 3.9 U/GPL and 2.8 ± 1.0 U/MPL) and normotensive pregnant women (6.4 ± 3.4 U/GPL and 3.0 ± 1.8 U/MPL). None of the values of the aCL were considered as positive. Conclusion: Serum aCL levels were similar in patients with different grades of preeclampsia-eclampsia and women with normotensive pregnancy.

show abstract

“…However, some antibodies (anti-β2GPI) in general obstetric populations seem to have a predictive value for the occurrence of preeclampsia and eclampsia [22].…”

Section: Aps Apl and Pregnancy Outcomementioning

confidence: 98%

Neonatal effects of maternal antiphospholipid syndrome

Tincani

Rebaioli²,

Andréoli³

et al. 2009

Curr Rheumatol Rep

Self Cite

View full text Add to dashboard Cite

Antiphospholipid antibodies (aPL) can impair the physiologic development of a fetus during pregnancy not only by causing thrombosis of the placental vessels, but also by directly binding throphoblast cells and modifying their functions. Consequently, the presence of aPL in pregnant women is linked to an increased rate of pregnancy complications. These include recurrent early miscarriages, late fetal losses, and hypertensive disorders of gestation. In this clinical setting, preeclampsia is usually early and severe and can be complicated by the syndrome of hemolysis, elevated liver enzymes, and low platelet count (HELLP syndrome). The close association between aPL and obstetric pathology supports the inclusion of these manifestations in the clinical classification criteria of antiphospholipid syndrome. About 30% of children born to mothers with aPL passively acquire these autoantibodies; fortunately, the occurrence of thrombosis seems extremely rare in these babies. The prospective ongoing studies of children born to antiphospholipid syndrome patients reassure us about their general good health; however, some data suggest that learning difficulties might occur, possibly related to in utero exposure to aPL.

show abstract

Anti-beta 2 glycoprotein I antibodies in a general obstetric population: preliminary results on the prevalence and correlation with pregnancy outcome. Anti-β2 glycoprotein I antibodies are associated with some obstetrical complications, mainly preeclampsia-eclampsia

Cited by 86 publications

References 21 publications

Do antiphospholipid antibodies cause preeclampsia and HELLP syndrome?

Do antiphospholipid antibodies cause preeclampsia and HELLP syndrome?

Anticardiolipin Antibodies and the Severity of Preeclampsia-Eclampsia

Neonatal effects of maternal antiphospholipid syndrome

Contact Info

Product

Resources

About